Pfizer’s gene-therapy trial failure boosts Sarepta’s stock
Pfizer’s gene-therapy trial failure boosts Sarepta’s stock
Shares of Sarepta Therapeutics climbed early Thursday after a potential competitor to its gene therapy stumbled in a late-stage trial.
